Herantis Pharma is a publicly listed (HRTIS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, the two ongoing clinical development programs explore the potential of our novel drug candidates in Parkinson’s disease and secondary lymphedema.
For Parkinson’s disease, our neuroprotective and neurorestorative drug candidate CDNF is intended to become the first disease-modifying treatment with further potential in other neurodegenerative diseases.
Our Lymfactin® gene therapy is targeted as the first curative drug for the treatment of cancer associated secondary lymphedema.
Both Parkinson’s disease and lymphedema remain conditions in which current treatments only address symptoms and therefore do not enable long-term improvement for patients. To successfully move forward our vision of breaking the boundaries of standard therapeutic approaches, Herantis has assembled a group of highly experienced professionals for the team, Board of Directors and Scientific Advisory Board.